Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer

By sjmartinez • April 14, 2024

Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers (Basel). 2024 Mar 28;16(7):1323. doi: 10.3390/cancers16071323. PMID: 38611000; PMCID: PMC11010910.

Tags: gemcitabine, Hematology/Oncology, metastatic pancreatic cancer, nabpaclitaxel, olaratumab, Publications

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]

Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation

Saco JD, Karin D, Patten JJ, Bachl S, Ching C, Kale N, Fan Y, Medina E, Naser Al Deen N, Champhekar A, Kaelin WG, Schulman[...]

Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance

Nishimura RN, Gera JF. Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance. Int J Mol Sci. 2026 Sep[...]